References
- Löfdahl C G, Chung K F. Long-acting β2-adrenoceptor agonists: A new perspective in the treatment of asthma. Eur Respir J 1991; 4: 218–226
- Löfdahl C G, Svedmyr N. Effect duration of inhaled formoterol, a new β2-adrenoceptor agonist, compared to salbutamol in asthmatic patients. Acta Pharmacol Toxicol 1986; II(Suppl 5)229, (A1358)
- Löfdahl C G, Svedmyr N. Formoterol fumarate, a new B-2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration. Allergy 1989; 44: 264–271
- Maesen F PV, Smeets J J, Gubbelmans H LL, Zweers P GMA. Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours. Chest 1990; 97: 590–594
- Becker A B, Simons F ER. Formoterol a new long-acting selective beta2-agonist, decreases airway responsiveness in children with asthma. Lung 1990; 168: 99–102, (Suppl)
- Graff-Lonnevig V, Browald L. Twelve hours' bron-chodilating effect of inhaled formoterol in children with asthma. A double blind crossover study vs. salbutamol. Clin Exp Allergy 1990; 20: 429–432
- Maesen F, Smeets J, Gubbelmans H, Zweers P. Formoterol in the treatment of nocturnal asthma. Chest 1990; 98: 866–870
- Ramsdale E H, Otis J, Kline P A, Gontovnick L S, Hargreave F E, O'Byrne P M. Prolonged protection against metacholin-induced bronchoconstriction by the inhaled β2-agonist formoterol. Am Rev Respir Dis 1991; 143: 998–1001
- von Berg A, Berdel D. Formoterol and salbutamol metered aerosols. Comparison of a new and an established beta-2-agonist for their bronchodilating efficacy in the treatment of childhood bronchial asthma. Pediatr Pulmonol 1989; 7: 89–93
- Arvidsson P, Larsson S, Löfdahl C G, Melander B, Wahlander L, Svedmyr N. Formoterol, a new long-acting bronchodilator for inhalation. Eur Respir J 1989; 2: 325–330
- Arvidsson P, Larsson S, Löfdahl C G, Melander B, Svedmyr N, Wahlander L. Inhaled formoterol during one year in asthma: A comparison with salbutamol. Eur Respir J 1991; 4: 1168–1173
- Wallin A, Melander B, Rosenhall L, Sandström T, Wahlander L. Formoterol, a new long acting beta2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma. Thorax 1990; 45: 259–261
- Kesten S, Chapman K R, Broder I, Cartier A, Hy-Land R H, Knight A, Malo J L, Mazza J A, Moote D W, Small P, Tarlo S, Gontovnick L, Rebuck A S. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis 1991; 144(3)622–625
- Britton J, Tattersfield A. Comparison of cumulative and noncumulative techniques to measure dose-response curves for beta agonists in patients with asthma. Thorax 1984; 39: 597–599